Colin Milde
REGISTER
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

Colin Milde

Forum Replies Created

Viewing 2 reply threads
  • Replies
      • June 29, 2013 at 3:46 pm
      Colin Milde
      Participant
        My name is Colin. I was on interferon for 32 months, with ribaviron the last 6 months. That was 10 years ago. I’m still completely insane. Any thoughts?
        • June 29, 2013 at 3:46 pm
        Colin Milde
        Participant
          My name is Colin. I was on interferon for 32 months, with ribaviron the last 6 months. That was 10 years ago. I’m still completely insane. Any thoughts?
          • June 29, 2013 at 3:46 pm
          Colin Milde
          Participant
            My name is Colin. I was on interferon for 32 months, with ribaviron the last 6 months. That was 10 years ago. I’m still completely insane. Any thoughts?
        Viewing 2 reply threads
        About the MRF Patient Forum

        The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

        The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

        Popular Topics